These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28806948)

  • 61. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
    Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
    Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
    [TBL] [Abstract][Full Text] [Related]  

  • 62. (125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics.
    Henderson A; Cahill D; Laing RW; Langley SE
    BJU Int; 2002 Oct; 90(6):567-72. PubMed ID: 12230619
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Test - retest reliability of the Indonesian version of the Overactive Bladder Symptom Score (OABSS) and its correlation with standard assessment tools.
    Sumardi R; Mochtar CA; Junizaf ; Santoso BI; Tjahjodjati ; Purwara BH; Hardjowijoto S; Paraton H; Yunaidi DA
    Acta Med Indones; 2012 Jul; 44(3):214-21. PubMed ID: 22983076
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL.
    Dallas NL; Malone PR; Jones A; Doggart AJ; McConway KJ; Rogers PB
    BJU Int; 2012 Aug; 110(3):383-90. PubMed ID: 22332791
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer.
    Kanai K; Nakashima J; Sugawara A; Shigematsu N; Nagata H; Kikuchi E; Miyajima A; Nakagawa K; Kubo A; Oya M
    Int J Clin Oncol; 2009 Dec; 14(6):502-6. PubMed ID: 19967485
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup.
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Brachytherapy; 2006; 5(2):122-6. PubMed ID: 16644467
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up.
    Caloglu M; Ciezki JP; Reddy CA; Angermeier K; Ulchaker J; Chehade N; Altman A; Magi-Galuzzi C; Klein EA
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):735-41. PubMed ID: 20646846
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy--morbidity and outcome results.
    Aaltomaa SH; Kataja VV; Lahtinen T; Palmgren JE; Forsell T
    Radiother Oncol; 2009 May; 91(2):213-6. PubMed ID: 19167119
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of patient-reported acute urinary and sexual toxicity scores in a 6- versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy.
    Ragab O; Banerjee R; Park SJ; Patel S; Zhang M; Wang J; Velez M; Demanes DJ; Kamrava M
    J Med Imaging Radiat Oncol; 2018 Feb; 62(1):109-115. PubMed ID: 28856847
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.
    Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Morizawa Y; Hori S; Owari T; Fujii T; Yamaki K; Hasegawa M; Fujimoto K
    Jpn J Clin Oncol; 2020 Jan; 50(1):58-65. PubMed ID: 31665354
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
    Cho HJ; Shin SC; Seo DY; Cho JM; Kang JY; Yoo TK; Yu JH; Sung LH; Moon HS
    Int J Clin Pract; 2014 Apr; 68(4):471-7. PubMed ID: 24471868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
    Patel DN; Feng T; Simon RM; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Roehrborn C; Andriole GL; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):238-244. PubMed ID: 29795141
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term urinary quality of life after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):454-61. PubMed ID: 12738320
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Permanent iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience].
    Bladou F; Salem N; Simonian-Sauve M; Rosello R; Ternier F; Resbeut M; Alzieu C; Karsenty G; Serment G; Gravis G; Maraninchi D
    Prog Urol; 2004 Jun; 14(3):345-52. PubMed ID: 15373176
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Unusually high prostate-specific antigen bounce after prostate brachytherapy: Searching for etiologic factors.
    Chira C; Taussky D; Gruszczynski N; Meissner A; Larrivée S; Carrier JF; Donath D; Delouya G
    Brachytherapy; 2013; 12(6):603-7. PubMed ID: 23891340
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of the overactive bladder symptom score and the overactive bladder symptom score derived from the bladder diaries.
    Hikita KS; Honda M; Hirano S; Kawamoto B; Panagiota T; Muraoka K; Sejima T; Takenaka A
    Neurourol Urodyn; 2016 Mar; 35(3):349-53. PubMed ID: 25597478
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.